Chatbot for Smoking Cessation
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this randomized study is to assess if a conversational agent (or chatbot) that the investigators have developed to help with quitting smoking is acceptable to people trying to quit smoking and to also collect initial information regarding its effectiveness.
In this study, some participants trying to quit smoking will be provided with this chatbot while other participants will not be
Are You a Good Fit for This Trial?
This trial is for native English-speaking Black or African American individuals, at least 21 years old, living in Minnesota who smoke regularly and are willing to try quitting within the next month. Participants must have a smartphone capable of running the study app and be able to upload data from it.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are provided with a chatbot to assist with smoking cessation, or are part of a control group
Follow-up
Participants are monitored for the effectiveness of the chatbot and their motivation to quit smoking
What Are the Treatments Tested in This Trial?
Interventions
- Chatbot
Trial Overview
The PASCAL Feasibility Study is testing whether a chatbot can help people quit smoking. It randomly assigns participants into two groups: one will use the chatbot along with their quit attempt, while the other group will not receive any chatbot assistance.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Minnesota
Lead Sponsor
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.